

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/891,093	06/25/2001	Sidney Pestka	PBLI-P08-005	9195
28120	7590 10/16/2003		EXAMI	INER
ROPES & GRAY LLP			MERTZ, PREMA MARIA	
ONE INTERNATIONAL PLACE BOSTON, MA 02110-2624			ART UNIT	PAPER NUMBER
			1646	1646

DATE MAILED: 10/16/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	A District No.	A!:
	Application No.	Applicant(s)
Advisory Action	09/891,093	PESTKA, SIDNEY
•	Examiner	Art Unit
	Prema M Mertz	1646
Th MAILING DATE of this communication appe	ears on the cover sheet with the o	correspondence address
THE REPLY FILED FAILS TO PLACE THIS APPI Therefore, further action by the applicant is required to ave final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.) a timely filed amendment whicl	ation. A proper reply to an places the application in
PERIOD FOR RE	<u>:PLY</u> [check either a) or b)]	
a) The period for reply expires 6 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire leading ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF TH	g date of the final rejection. HE FINAL REJECTION. See MPEP
Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of 1 (2) as set forth in (b) above, if checked. Any reply received by the Office timely filed, may reduce any earned patent term adjustment. See 37 C	of extension and the corresponding amo the shortened statutory period for reply the later than three months after the mail	unt of the fee. The appropriate extension originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF		
2. \boxtimes The proposed amendment(s) will not be entered be	ecause:	
(a) X they raise new issues that would require further	er consideration and/or search (s	see NOTE below);
(b) they raise the issue of new matter (see Note b	elow);	
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mate	rially reducing or simplifying the
(d) they present additional claims without cancel	ng a corresponding number of fi	nally rejected claims.
NOTE: See Continuation Sheet.		
3. Applicant's reply has overcome the following reject	ion(s):	
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because:		dered but does NOT place the
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY t	o issues which were newly
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we		
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected: <u>18-20,37 and 38</u> .		
Claim(s) withdrawn from consideration:		
8. The proposed drawing correction filed on is	a) approved or b) disapp	roved by the Examiner.
9. Note the attached Information Disclosure Statemer	nt(s)(PTO-1449)	
10. Other:	, , –	
		Freme Mung Prema M Mertz Primary Examiner Art Unit: 1646

Application No. 09/891,093

Continuation Sheet (PTOL-303)

Continuation of 2. NOTE: The recitation of new limitations 6XSSC at 0 C(line 7) and mutant cytokine (line 2) precipitates 35 USC 112, second para rejections because 6XSSC is a very low stringency wash and at this temperature any nucleic acid can be made to hybridize to another. The metes and bounds of the term "mutant cytokine" are unclear because it is vague as to which cytokines from the hundreds of known cytokines and those yet to be discovered are encompassed by the instant claim. Furthermore, Applicants have failed to obviate the 35 USC 112 first paragraph, written description rejection of record.